Improved Cancer Detection Using Artificial Intelligence: a Retrospective Evaluation of Missed Cancers on Mammography

Enhancing detection of previously missed non-palpable breast carcinomas through artificial intelligence

Purpose

To investigate the impact of artificial intelligence (AI) reading digital mammograms in increasing the chance of detecting missed breast cancer, by studying the AI- flagged early morphology indictors, overlooked by the radiologist, and correlating them with the missed cancer pathology types.

Methods and materials

Mammograms done in 2020-2023, presenting breast carcinomas (n = 1998), were analyzed in concordance with the prior one year's result (2019-2022) assumed negative or benign. Present mammograms reviewed for the descriptors: asymmetry, distortion, mass, and microcalcifications. The AI presented abnormalities by overlaying color hue and scoring percentage for the degree of suspicion of malignancy.

Results

Prior mammogram with AI marking compromised 54 % (n = 555), and in the present mammograms, AI targeted 904 (88 %) carcinomas. The descriptor proportion of "asymmetry" was the common presentation of missed breast carcinoma (64.1 %) in the prior mammograms and the highest detection rate for AI was presented by "distortion" (100 %) followed by "grouped microcalcifications" (80 %). AI performance to predict malignancy in previously assigned negative or benign mammograms showed sensitivity of 73.4 %, specificity of 89 %, and accuracy of 78.4 %.

Conclusions

Reading mammograms with AI significantly enhances the detection of early cancerous changes, particularly in dense breast tissues. The AI's detection rate does not correlate with specific pathological types of breast cancer, highlighting its broad utility. Subtle mammographic changes in postmenopausal women, not corroborated by ultrasound but marked by AI, warrant further evaluation by advanced applications of digital mammograms and close interval AI-reading mammogram follow up to minimize the potential for missed breast carcinoma.

Role of AI in empowering and redefining the oncology care landscape: perspective from a developing nation

Early diagnosis and accurate prognosis play a pivotal role in the clinical management of cancer and in preventing cancer-related mortalities. The burgeoning population of Asia in general and South Asian countries like India in particular pose significant challenges to the healthcare system. Regrettably, the demand for healthcare services in India far exceeds the available resources, resulting in overcrowded hospitals, prolonged wait times, and inadequate facilities. The scarcity of trained manpower in rural settings, lack of awareness and low penetrance of screening programs further compounded the problem. Artificial Intelligence (AI), driven by advancements in machine learning, deep learning, and natural language processing, can profoundly transform the underlying shortcomings in the healthcare industry, more for populous nations like India. With about 1.4 million cancer cases reported annually and 0.9 million deaths, India has a significant cancer burden that surpassed several nations. Further, India's diverse and large ethnic population is a data goldmine for healthcare research. Under these circumstances, AI-assisted technology, coupled with digital health solutions, could support effective oncology care and reduce the economic burden of GDP loss in terms of years of potential productive life lost (YPPLL) due to India's stupendous cancer burden. This review explores different aspects of cancer management, such as prevention, diagnosis, precision treatment, prognosis, and drug discovery, where AI has demonstrated promising clinical results. By harnessing the capabilities of AI in oncology research, healthcare professionals can enhance their ability to diagnose cancers at earlier stages, leading to more effective treatments and improved patient outcomes. With continued research and development, AI and digital health can play a transformative role in mitigating the challenges posed by the growing population and advancing the fight against cancer in India. Moreover, AI-driven technologies can assist in tailoring personalized treatment plans, optimizing therapeutic strategies, and supporting oncologists in making well-informed decisions. However, it is essential to ensure responsible implementation and address potential ethical and privacy concerns associated with using AI in healthcare.

Artificial intelligence versus radiologists in detecting early-stage breast cancer from mammograms: a meta-analysis of paradigm shifts

Purpose

Early detection of breast cancer is crucial for improving patient outcomes. With advancements in artificial intelligence (AI), there is growing interest in its potential to assist radiologists in interpreting mammograms for early cancer detection. AI algorithms offer the promise of increased accuracy and efficiency in identifying subtle signs of breast cancer, potentially complementing the expertise of radiologists and enhancing the screening process for early-stage breast cancer detection.

Material and methods

A systematic literature review was conducted to identify and select original research reports on breast cancer diagnosis by artificial intelligence versus conventional radiologists in using mammograms in accordance with the PRISMA guidelines. Data were analysed with Review Manager version 5.4. P-value and I2 were used to test the significance of differences.

Results

This systematic review and meta-analysis included 8 studies with data from a total of 120,950 patients. Regarding the sensitivity of AI, the pooled analysis of 6 studies with sensitivities ranging from 0.70 to 0.89 yielded a sensitivity of 0.85. However, the sensitivity of the radiologists ranged from 0.63 to 0.85, with an overall sensitivity of 0.77. As for specificity, both radiologists and AI groups had closer results.

Conclusions

The comparison between AI systems and radiologists in detecting early-stage breast cancer from mammograms highlights the potential of AI as a valuable tool in breast cancer screening. While AI algorithms have shown promising results in terms of accuracy and efficiency, they should be viewed as complementary to radiologists rather than replacements.

A real world evaluation of an innovative artificial intelligence tool for population-level breast cancer screening

In resource-constrained countries like India, mammography-based breast screening is challenging to implement. This state-wide study, funded by the Government of Punjab, evaluated the use of Thermalytix, a low-cost, radiation-free AI tool, for breast cancer screening. Community health workers, trained to raise awareness, mobilized women aged 30 and above for screening. Thermalytix triaged women into five risk categories based on thermal images, with high-risk women recalled for diagnostic imaging. Over 18 months, 15,069 women were screened across 183 locations in Punjab. The median age was 41 years, and 69.9% were asymptomatic. Of 460 women testing positive (recall rate 3.1%), 268 underwent follow-up imaging, and 27 were confirmed with breast cancer, yielding a detection rate of 0.18%. The positive predictive value of biopsy performed was 81.81%, and the median diagnostic interval was 21 days, with therapy initiation within 30 days. The study demonstrates the potential of Thermalytix for effective population-level breast cancer screening in low-resource settings.

Artificial intelligence for breast cancer detection and its health technology assessment: A scoping review

BACKGROUND

Recent healthcare advancements highlight the potential of Artificial Intelligence (AI) - and especially, among its subfields, Machine Learning (ML) - in enhancing Breast Cancer (BC) clinical care, leading to improved patient outcomes and increased radiologists' efficiency. While medical imaging techniques have significantly contributed to BC detection and diagnosis, their synergy with AI algorithms has consistently demonstrated superior diagnostic accuracy, reduced False Positives (FPs), and enabled personalized treatment strategies. Despite the burgeoning enthusiasm for leveraging AI for early and effective BC clinical care, its widespread integration into clinical practice is yet to be realized, and the evaluation of AI-based health technologies in terms of health and economic outcomes remains an ongoing endeavor.

OBJECTIVES

This scoping review aims to investigate AI (and especially ML) applications that have been implemented and evaluated across diverse clinical tasks or decisions in breast imaging and to explore the current state of evidence concerning the assessment of AI-based technologies for BC clinical care within the context of Health Technology Assessment (HTA).

METHODS

We conducted a systematic literature search following the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) checklist in PubMed and Scopus to identify relevant studies on AI (and particularly ML) applications in BC detection and diagnosis. We limited our search to studies published from January 2015 to October 2023. The Minimum Information about CLinical Artificial Intelligence Modeling (MI-CLAIM) checklist was used to assess the quality of AI algorithms development, evaluation, and reporting quality in the reviewed articles. The HTA Core Model® was also used to analyze the comprehensiveness, robustness, and reliability of the reported results and evidence in AI-systems' evaluations to ensure rigorous assessment of AI systems' utility and cost-effectiveness in clinical practice.

RESULTS

Of the 1652 initially identified articles, 104 were deemed eligible for inclusion in the review. Most studies examined the clinical effectiveness of AI-based systems (78.84%, n= 82), with one study focusing on safety in clinical settings, and 13.46% (n=14) focusing on patients' benefits. Of the studies, 31.73% (n=33) were ethically approved to be carried out in clinical practice, whereas 25% (n=26) evaluated AI systems legally approved for clinical use. Notably, none of the studies addressed the organizational implications of AI systems in clinical practice. Of the 104 studies, only two of them focused on cost-effectiveness analysis, and were analyzed separately. The average percentage scores for the first 102 AI-based studies' quality assessment based on the MI-CLAIM checklist criteria were 84.12%, 83.92%, 83.98%, 74.51%, and 14.7% for study design, data and optimization, model performance, model examination, and reproducibility, respectively. Notably, 20.59% (n=21) of these studies relied on large-scale representative real-world breast screening datasets, with only 10.78% (n =11) studies demonstrating the robustness and generalizability of the evaluated AI systems.

CONCLUSION

In bridging the gap between cutting-edge developments and seamless integration of AI systems into clinical workflows, persistent challenges encompass data quality and availability, ethical and legal considerations, robustness and trustworthiness, scalability, and alignment with existing radiologists' workflow. These hurdles impede the synthesis of comprehensive, robust, and reliable evidence to substantiate these systems' clinical utility, relevance, and cost-effectiveness in real-world clinical workflows. Consequently, evaluating AI-based health technologies through established HTA methodologies becomes complicated. We also highlight potential significant influences on AI systems' effectiveness of various factors, such as operational dynamics, organizational structure, the application context of AI systems, and practices in breast screening or examination reading of AI support tools in radiology. Furthermore, we emphasize substantial reciprocal influences on decision-making processes between AI systems and radiologists. Thus, we advocate for an adapted assessment framework specifically designed to address these potential influences on AI systems' effectiveness, mainly addressing system-level transformative implications for AI systems rather than focusing solely on technical performance and task-level evaluations.

Artificial intelligence in mammography: a systematic review of the external validation

Objective

To conduct a systematic review of external validation studies on the use of different Artificial Intelligence algorithms in breast cancer screening with mammography.

Data source

Our systematic review was conducted and reported following the PRISMA statement, using the PubMed, EMBASE, and Cochrane databases with the search terms "Artificial Intelligence," "Mammography," and their respective MeSH terms. We filtered publications from the past ten years (2014 - 2024) and in English.

Study selection

A total of 1,878 articles were found in the databases used in the research. After removing duplicates (373) and excluding those that did not address our PICO question (1,475), 30 studies were included in this work.

Data collection

The data from the studies were collected independently by five authors, and it was subsequently synthesized based on sample data, location, year, and their main results in terms of AUC, sensitivity, and specificity.

Data synthesis

It was demonstrated that the Area Under the ROC Curve (AUC) and sensitivity were similar to those of radiologists when using independent Artificial Intelligence. When used in conjunction with radiologists, statistically higher accuracy in mammogram evaluation was reported compared to the assessment by radiologists alone.

Conclusion

AI algorithms have emerged as a means to complement and enhance the performance and accuracy of radiologists. They also assist less experienced professionals in detecting possible lesions. Furthermore, this tool can be used to complement and improve the analyses conducted by medical professionals.

Diagnostic capabilities of artificial intelligence as an additional reader in a breast cancer screening program

OBJECTIVES

We aimed to evaluate the early-detection capabilities of AI in a screening program over its duration, with a specific focus on the detection of interval cancers, the early detection of cancers with the assistance of AI from prior visits, and its impact on workload for various reading scenarios.

MATERIALS AND METHODS

The study included 22,621 mammograms of 8825 women within a 10-year biennial two-reader screening program. The statistical analysis focused on 5136 mammograms from 4282 women due to data retrieval issues, among whom 105 were diagnosed with breast cancer. The AI software assigned scores from 1 to 100. Histopathology results determined the ground truth, and Youden's index was used to establish a threshold. Tumor characteristics were analyzed with ANOVA and chi-squared test, and different workflow scenarios were evaluated using bootstrapping.

RESULTS

The AI software achieved an AUC of 89.6% (86.1-93.2%, 95% CI). The optimal threshold was 30.44, yielding 72.38% sensitivity and 92.86% specificity. Initially, AI identified 57 screening-detected cancers (83.82%), 15 interval cancers (51.72%), and 4 missed cancers (50%). AI as a second reader could have led to earlier diagnosis in 24 patients (average 29.92 ± 19.67 months earlier). No significant differences were found in cancer-characteristics groups. A hybrid triage workflow scenario showed a potential 69.5% reduction in workload and a 30.5% increase in accuracy.

CONCLUSION

This AI system exhibits high sensitivity and specificity in screening mammograms, effectively identifying interval and missed cancers and identifying 23% of cancers earlier in prior mammograms. Adopting AI as a triage mechanism has the potential to reduce workload by nearly 70%.

CLINICAL RELEVANCE STATEMENT

The study proposes a more efficient method for screening programs, both in terms of workload and accuracy.

KEY POINTS

• Incorporating AI as a triage tool in screening workflow improves sensitivity (72.38%) and specificity (92.86%), enhancing detection rates for interval and missed cancers. • AI-assisted triaging is effective in differentiating low and high-risk cases, reduces radiologist workload, and potentially enables broader screening coverage. • AI has the potential to facilitate early diagnosis compared to human reading.

Is the development of liquid biopsy for the early detection and the monitoring of breast cancers on its way of overtaking mammography?

Mammography, as of today, is used as a gold standard for screening, diagnosing, and monitoring breast cancer (BC). While overall beneficial, it presents several downsides, such as limitations in accuracy, relatively high costs, and dependence on heavy infrastructure, greatly limiting accessibility for the entire global target population. There is currently no established alternative to mammography, and overcoming this major challenge is a hot topic in research and technology. One avenue for tackling this issue is the development of highly sensitive and specific non-invasive blood tests for the early diagnosis and follow-up of breast cancer. This paper discusses the limitations of mammography and recapitulates the blood tests already available, those under development, and future developments in this field.

Reproducibility and Explainability of Deep Learning in Mammography: A Systematic Review of Literature

Background  Although abundant literature is currently available on the use of deep learning for breast cancer detection in mammography, the quality of such literature is widely variable. Purpose  To evaluate published literature on breast cancer detection in mammography for reproducibility and to ascertain best practices for model design. Methods  The PubMed and Scopus databases were searched to identify records that described the use of deep learning to detect lesions or classify images into cancer or noncancer. A modification of Quality Assessment of Diagnostic Accuracy Studies (mQUADAS-2) tool was developed for this review and was applied to the included studies. Results of reported studies (area under curve [AUC] of receiver operator curve [ROC] curve, sensitivity, specificity) were recorded. Results  A total of 12,123 records were screened, of which 107 fit the inclusion criteria. Training and test datasets, key idea behind model architecture, and results were recorded for these studies. Based on mQUADAS-2 assessment, 103 studies had high risk of bias due to nonrepresentative patient selection. Four studies were of adequate quality, of which three trained their own model, and one used a commercial network. Ensemble models were used in two of these. Common strategies used for model training included patch classifiers, image classification networks (ResNet in 67%), and object detection networks (RetinaNet in 67%). The highest reported AUC was 0.927 ± 0.008 on a screening dataset, while it reached 0.945 (0.919-0.968) on an enriched subset. Higher values of AUC (0.955) and specificity (98.5%) were reached when combined radiologist and Artificial Intelligence readings were used than either of them alone. None of the studies provided explainability beyond localization accuracy. None of the studies have studied interaction between AI and radiologist in a real world setting. Conclusion  While deep learning holds much promise in mammography interpretation, evaluation in a reproducible clinical setting and explainable networks are the need of the hour.

Deep Learning in Breast Cancer Imaging: State of the Art and Recent Advancements in Early 2024

The rapid advancement of artificial intelligence (AI) has significantly impacted various aspects of healthcare, particularly in the medical imaging field. This review focuses on recent developments in the application of deep learning (DL) techniques to breast cancer imaging. DL models, a subset of AI algorithms inspired by human brain architecture, have demonstrated remarkable success in analyzing complex medical images, enhancing diagnostic precision, and streamlining workflows. DL models have been applied to breast cancer diagnosis via mammography, ultrasonography, and magnetic resonance imaging. Furthermore, DL-based radiomic approaches may play a role in breast cancer risk assessment, prognosis prediction, and therapeutic response monitoring. Nevertheless, several challenges have limited the widespread adoption of AI techniques in clinical practice, emphasizing the importance of rigorous validation, interpretability, and technical considerations when implementing DL solutions. By examining fundamental concepts in DL techniques applied to medical imaging and synthesizing the latest advancements and trends, this narrative review aims to provide valuable and up-to-date insights for radiologists seeking to harness the power of AI in breast cancer care.

The Role of AI in Hospitals and Clinics: Transforming Healthcare in the 21st Century

As healthcare systems around the world face challenges such as escalating costs, limited access, and growing demand for personalized care, artificial intelligence (AI) is emerging as a key force for transformation. This review is motivated by the urgent need to harness AI's potential to mitigate these issues and aims to critically assess AI's integration in different healthcare domains. We explore how AI empowers clinical decision-making, optimizes hospital operation and management, refines medical image analysis, and revolutionizes patient care and monitoring through AI-powered wearables. Through several case studies, we review how AI has transformed specific healthcare domains and discuss the remaining challenges and possible solutions. Additionally, we will discuss methodologies for assessing AI healthcare solutions, ethical challenges of AI deployment, and the importance of data privacy and bias mitigation for responsible technology use. By presenting a critical assessment of AI's transformative potential, this review equips researchers with a deeper understanding of AI's current and future impact on healthcare. It encourages an interdisciplinary dialogue between researchers, clinicians, and technologists to navigate the complexities of AI implementation, fostering the development of AI-driven solutions that prioritize ethical standards, equity, and a patient-centered approach.

Localization of contrast-enhanced breast lesions in ultrafast screening MRI using deep convolutional neural networks

OBJECTIVES

To develop a deep learning-based method for contrast-enhanced breast lesion detection in ultrafast screening MRI.

MATERIALS AND METHODS

A total of 837 breast MRI exams of 488 consecutive patients were included. Lesion's location was independently annotated in the maximum intensity projection (MIP) image of the last time-resolved angiography with stochastic trajectories (TWIST) sequence for each individual breast, resulting in 265 lesions (190 benign, 75 malignant) in 163 breasts (133 women). YOLOv5 models were fine-tuned using training sets containing the same number of MIP images with and without lesions. A long short-term memory (LSTM) network was employed to help reduce false positive predictions. The integrated system was then evaluated on test sets containing enriched uninvolved breasts during cross-validation to mimic the performance in a screening scenario.

RESULTS

In five-fold cross-validation, the YOLOv5x model showed a sensitivity of 0.95, 0.97, 0.98, and 0.99, with 0.125, 0.25, 0.5, and 1 false positive per breast, respectively. The LSTM network reduced 15.5% of the false positive prediction from the YOLO model, and the positive predictive value was increased from 0.22 to 0.25.

CONCLUSIONS

A fine-tuned YOLOv5x model can detect breast lesions on ultrafast MRI with high sensitivity in a screening population, and the output of the model could be further refined by an LSTM network to reduce the amount of false positive predictions.

CLINICAL RELEVANCE STATEMENT

The proposed integrated system would make the ultrafast MRI screening process more effective by assisting radiologists in prioritizing suspicious examinations and supporting the diagnostic workup.

KEY POINTS

• Deep convolutional neural networks could be utilized to automatically pinpoint breast lesions in screening MRI with high sensitivity. • False positive predictions significantly increased when the detection models were tested on highly unbalanced test sets with more normal scans. • Dynamic enhancement patterns of breast lesions during contrast inflow learned by the long short-term memory networks helped to reduce false positive predictions.

Deep Attention Q-Network for Personalized Treatment Recommendation

Tailoring treatment for severely ill patients is crucial yet challenging to achieve optimal healthcare outcomes. Recent advances in reinforcement learning offer promising personalized treatment recommendations. However, they often rely solely on a patient's current physiological state, which may not accurately represent the true health status of the patient. This limitation hampers policy learning and evaluation, undermining the effectiveness of the treatment. In this study, we propose Deep Attention Q-Network for personalized treatment recommendation, leveraging the Transformer architecture within a deep reinforcement learning framework to efficiently integrate historical observations of patients. We evaluated our proposed method on two real-world datasets: sepsis and acute hypotension patients, demonstrating its superiority over state-of-the-art methods. The source code for our model is available at https://github.com/stevenmsm/RL-ICU-DAQN.

Recent advancements in artificial intelligence for breast cancer: Image augmentation, segmentation, diagnosis, and prognosis approaches

Breast cancer is a significant global health burden, with increasing morbidity and mortality worldwide. Early screening and accurate diagnosis are crucial for improving prognosis. Radiographic imaging modalities such as digital mammography (DM), digital breast tomosynthesis (DBT), magnetic resonance imaging (MRI), ultrasound (US), and nuclear medicine techniques, are commonly used for breast cancer assessment. And histopathology (HP) serves as the gold standard for confirming malignancy. Artificial intelligence (AI) technologies show great potential for quantitative representation of medical images to effectively assist in segmentation, diagnosis, and prognosis of breast cancer. In this review, we overview the recent advancements of AI technologies for breast cancer, including 1) improving image quality by data augmentation, 2) fast detection and segmentation of breast lesions and diagnosis of malignancy, 3) biological characterization of the cancer such as staging and subtyping by AI-based classification technologies, 4) prediction of clinical outcomes such as metastasis, treatment response, and survival by integrating multi-omics data. Then, we then summarize large-scale databases available to help train robust, generalizable, and reproducible deep learning models. Furthermore, we conclude the challenges faced by AI in real-world applications, including data curating, model interpretability, and practice regulations. Besides, we expect that clinical implementation of AI will provide important guidance for the patient-tailored management.

Effect of artificial intelligence-based computer-aided diagnosis on the screening outcomes of digital mammography: a matched cohort study

OBJECTIVE

To investigate whether artificial intelligence-based computer-aided diagnosis (AI-CAD) can improve radiologists' performance when used to support radiologists' interpretation of digital mammography (DM) in breast cancer screening.

METHODS

A retrospective database search identified 3158 asymptomatic Korean women who consecutively underwent screening DM between January and December 2019 without AI-CAD support, and screening DM between February and July 2020 with image interpretation aided by AI-CAD in a tertiary referral hospital using single reading. Propensity score matching was used to match the DM with AI-CAD group in a 1:1 ratio with the DM without AI-CAD group according to age, breast density, experience level of the interpreting radiologist, and screening round. Performance measures were compared with the McNemar test and generalized estimating equations.

RESULTS

A total of 1579 women who underwent DM with AI-CAD were matched with 1579 women who underwent DM without AI-CAD. Radiologists showed higher specificity (96% [1500 of 1563] vs 91.6% [1430 of 1561]; p < 0.001) and lower abnormal interpretation rates (AIR) (4.9% [77 of 1579] vs 9.2% [145 of 1579]; p < 0.001) with AI-CAD than without. There was no significant difference in the cancer detection rate (CDR) (AI-CAD vs no AI-CAD, 8.9 vs 8.9 per 1000 examinations; p = 0.999), sensitivity (87.5% vs 77.8%; p = 0.999), and positive predictive value for biopsy (PPV3) (35.0% vs 35.0%; p = 0.999) according to AI-CAD support.

CONCLUSIONS

AI-CAD increases the specificity for radiologists without decreasing sensitivity as a supportive tool in the single reading of DM for breast cancer screening.

CLINICAL RELEVANCE STATEMENT

This study shows that AI-CAD could improve the specificity of radiologists' DM interpretation in the single reading system without decreasing sensitivity, suggesting that it can benefit patients by reducing false positive and recall rates.

KEY POINTS

• In this retrospective-matched cohort study (DM without AI-CAD vs DM with AI-CAD), radiologists showed higher specificity and lower AIR when AI-CAD was used to support decision-making in DM screening. • CDR, sensitivity, and PPV for biopsy did not differ with and without AI-CAD support.

Evaluation of an Artificial Intelligence System for Detection of Invasive Lobular Carcinoma on Digital Mammography

Introduction Early breast cancer detection with screening mammography has been shown to reduce mortality and improve breast cancer survival. This study aims to evaluate the ability of an artificial intelligence computer-aided detection (AI CAD) system to detect biopsy-proven invasive lobular carcinoma (ILC) on digital mammography. Methods This retrospective study reviewed mammograms of patients who were diagnosed with biopsy-proved ILC between January 1, 2017, and January 1, 2022. All mammograms were analyzed using cmAssist^® (CureMetrix, San Diego, California, United States), which is an AI CAD for mammography. The AI CAD sensitivity for detecting ILC on mammography was calculated and further subdivided by lesion type, mass shape, and mass margins. To account for the within-subject correlation, generalized linear mixed models were implemented to investigate the association between age, family history, and breast density and whether the AI detected a false positive or true positive. Odds ratios, 95% confidence intervals, and p-values were also calculated. Results A total of 124 patients with 153 biopsy-proven ILC lesions were included. The AI CAD detected ILC on mammography with a sensitivity of 80%. The AI CAD had the highest sensitivity for detecting calcifications (100%), masses with irregular shape (82%), and masses with spiculated margins (86%). However, 88% of mammograms had at least one false positive mark with an average number of 3.9 false positive marks per mammogram. Conclusion The AI CAD system evaluated was successful in marking the malignancy in digital mammography. However, the numerous annotations confounded the ability to determine its overall accuracy and this reduces its potential use in real-life practice.

AI-Based CXR First Reading: Current Limitations to Ensure Practical Value

We performed a multicenter external evaluation of the practical and clinical efficacy of a commercial AI algorithm for chest X-ray (CXR) analysis (Lunit INSIGHT CXR). A retrospective evaluation was performed with a multi-reader study. For a prospective evaluation, the AI model was run on CXR studies; the results were compared to the reports of 226 radiologists. In the multi-reader study, the area under the curve (AUC), sensitivity, and specificity of the AI were 0.94 (CI95%: 0.87-1.0), 0.9 (CI95%: 0.79-1.0), and 0.89 (CI95%: 0.79-0.98); the AUC, sensitivity, and specificity of the radiologists were 0.97 (CI95%: 0.94-1.0), 0.9 (CI95%: 0.79-1.0), and 0.95 (CI95%: 0.89-1.0). In most regions of the ROC curve, the AI performed a little worse or at the same level as an average human reader. The McNemar test showed no statistically significant differences between AI and radiologists. In the prospective study with 4752 cases, the AUC, sensitivity, and specificity of the AI were 0.84 (CI95%: 0.82-0.86), 0.77 (CI95%: 0.73-0.80), and 0.81 (CI95%: 0.80-0.82). Lower accuracy values obtained during the prospective validation were mainly associated with false-positive findings considered by experts to be clinically insignificant and the false-negative omission of human-reported "opacity", "nodule", and calcification. In a large-scale prospective validation of the commercial AI algorithm in clinical practice, lower sensitivity and specificity values were obtained compared to the prior retrospective evaluation of the data of the same population.

The utilization of artificial intelligence applications to improve breast cancer detection and prognosis

Breast imaging faces challenges with the current increase in medical imaging requests and lesions that breast screening programs can miss. Solutions to improve these challenges are being sought with the recent advancement and adoption of artificial intelligent (AI)-based applications to enhance workflow efficiency as well as patient-healthcare outcomes. rtificial intelligent tools have been proposed and used to analyze different modes of breast imaging, in most of the published studies, mainly for the detection and classification of breast lesions, breast lesion segmentation, breast density evaluation, and breast cancer risk assessment. This article reviews the background of the Conventional Computer-aided Detection system and AI, AI-based applications in breast medical imaging for the identification, segmentation, and categorization of lesions, breast density and cancer risk evaluation. In addition, the challenges, and limitations of AI-based applications in breast imaging are also discussed.

Comparison of Diagnostic Performance in Mammography Assessment: Radiologist with Reference to Clinical Information Versus Standalone Artificial Intelligence Detection

We compared diagnostic performances between radiologists with reference to clinical information and standalone artificial intelligence (AI) detection of breast cancer on digital mammography. This study included 392 women (average age: 57.3 ± 12.1 years, range: 30−94 years) diagnosed with malignancy between January 2010 and June 2021 who underwent digital mammography prior to biopsy. Two radiologists assessed mammographic findings based on clinical symptoms and prior mammography. All mammographies were analyzed via AI. Breast cancer detection performance was compared between radiologists and AI based on how the lesion location was concordant between each analysis method (radiologists or AI) and pathological results. Kappa coefficient was used to measure the concordance between radiologists or AI analysis and pathology results. Binominal logistic regression analysis was performed to identify factors influencing the concordance between radiologists’ analysis and pathology results. Overall, the concordance was higher in radiologists’ diagnosis than on AI analysis (kappa coefficient: 0.819 vs. 0.698). Impact of prior mammography (odds ratio (OR): 8.55, p < 0.001), clinical symptom (OR: 5.49, p < 0.001), and fatty breast density (OR: 5.18, p = 0.008) were important factors contributing to the concordance of lesion location between radiologists’ diagnosis and pathology results.

Thermography as a Breast Cancer Screening Technique: A Review Article

Globally, breast cancer is the most frequently occurring cancer in women and is the reason for more disability-adjusted life years lost than any other type of cancer. Hence, early screening plays a vital role in reducing breast cancer mortality. Although mammography is the standard procedure used for screening and diagnosis of breast cancer, it still has some limitations. Other methods used for screening include ultrasound and clinical breast examination. Despite its limitations, mammography is the gold standard for screening breast malignancy. Another emerging method for screening is thermography. With recent technological advances, breast cancer screening through thermography has demonstrated several advantages over existing modalities. For this review, a literature search was performed using databases such as PubMed, Google Scholar, and ScienceDirect. The keywords searched included breast cancer, early detection, breast cancer screening, mammography, and thermography. This review discusses the benefits of thermography showing that it can be a significant modality for breast cancer screening. The recent developments in thermal sensors, imaging protocols, and computer-aided software diagnostics hold great promise for making this technique a mainstream screening method for cancer. Moreover, the use of artificial intelligence and thermal imaging to detect early-stage breast cancer can provide impressive results. Therefore, thermography will be a promising technology for the early detection of breast cancer.

Multicenter, Multivendor Validation of an FDA-approved Algorithm for Mammography Triage

OBJECTIVE

Artificial intelligence (AI)-based triage algorithms may improve cancer detection and expedite radiologist workflow. To this end, the performance of a commercial AI-based triage algorithm on screening mammograms was evaluated across breast densities and lesion types.

METHODS

This retrospective, IRB-exempt, multicenter, multivendor study examined 1255 screening 4-view mammograms (400 positive and 855 negative studies). Images were anonymized by providing institutions and analyzed by a commercially available AI algorithm (cmTriage, CureMetrix, La Jolla, CA) that performed retrospective triage at the study level by flagging exams as "suspicious" or not. Sensitivities and specificities with confidence intervals were derived from area under the curve (AUC) calculations.

RESULTS

The algorithm demonstrated an AUC of 0.95 (95% CI: 0.94-0.96) for case identification. Area under the curve held across densities (0.95) and lesion types (masses: 0.94 [95% CI: 0.92-0.96] or microcalcifications: 0.97 [95% CI: 0.96-0.99]). The algorithm has a default sensitivity of 93% (95% CI: 95.6%-90.5%) with specificity of 76.3% (95% CI: 79.2%-73.4%). To evaluate real-world performance, a sensitivity of 86.9% (95% CI: 83.6%-90.2%) was tested, as observed for practicing radiologists by the Breast Cancer Surveillance Consortium (BCSC) study. The resulting specificity was 88.5% (95% CI: 86.4%-90.7%), similar to the BCSC specificity of 88.9%, indicating performance comparable to real-world results.

CONCLUSION

When tested for lesion detection, an AI-based triage software can perform at the level of practicing radiologists. Drawing attention to suspicious exams may improve reader specificity and help streamline radiologist workflow, enabling faster turnaround times and improving care.

Mapping intellectual structures and research hotspots in the application of artificial intelligence in cancer: A bibliometric analysis

Background

Artificial intelligence (AI) is more and more widely used in cancer, which is of great help to doctors in diagnosis and treatment. This study aims to summarize the current research hotspots in the Application of Artificial Intelligence in Cancer (AAIC) and to assess the research trends in AAIC.

Methods

Scientific publications for AAIC-related research from 1 January 1998 to 1 July 2022 were obtained from the Web of Science database. The metrics analyses using bibliometrics software included publication, keyword, author, journal, institution, and country. In addition, the blustering analysis on the binary matrix was performed on hot keywords.

Results

The total number of papers in this study is 1592. The last decade of AAIC research has been divided into a slow development phase (2013-2018) and a rapid development phase (2019-2022). An international collaboration centered in the USA is dedicated to the development and application of AAIC. Li J is the most prolific writer in AAIC. Through clustering analysis and high-frequency keyword research, it has been shown that AI plays a significantly important role in the prediction, diagnosis, treatment and prognosis of cancer. Classification, diagnosis, carcinogenesis, risk, and validation are developing topics. Eight hotspot fields of AAIC were also identified.

Conclusion

AAIC can benefit cancer patients in diagnosing cancer, assessing the effectiveness of treatment, making a decision, predicting prognosis and saving costs. Future AAIC research may be dedicated to optimizing AI calculation tools, improving accuracy, and promoting AI.

Evaluation of an artificial intelligence support system for breast cancer screening in Chinese people based on mammogram

BACKGROUND

To evaluate the diagnostic performance of radiologists on breast cancer with or without artificial intelligence (AI) support.

METHODS

A retrospective study was performed. In total, 643 mammograms (average age: 54 years; female: 100%; cancer: 62.05%) were randomly allocated into two groups. Seventy-five percent of mammograms in each group were randomly selected for assessment by two independent radiologists, and the rest were read once. Half of the 71 radiologists could read mammograms with AI support, and the other half could not. Sensitivity, specificity, Youden's index, agreement rate, Kappa value, the area under the receiver operating characteristic curve (AUC) and the reading time of radiologists in each group were analyzed.

RESULTS

The average AUC was higher if the AI support system was used (unaided: 0.84; with AI support: 0.91; p < 0.01). The average sensitivity increased from 84.77% to 95.07% with AI support (p < 0.01), but the average specificity decreased (p = 0.07). Youden's index, agreement rate and Kappa value were larger in the group with AI support, and the average reading time was shorter (p < 0.01).

CONCLUSIONS

The AI support system might contribute to enhancing the diagnostic performance (e.g., higher sensitivity and AUC) of radiologists. In the future, the AI algorithm should be improved, and prospective studies should be conducted.

Does artificial intelligence aid in the detection of different types of breast cancer?

Background

On mammography many cancers may be missed even in retrospect either due to the breast density, the small size of the tumor or the subtle signs of cancer that are imperceptible. We aimed to compare the sensitivity of artificial intelligence (AI) to that of digital mammography in the detection of different types of breast cancer. Also, the sensitivity of AI in picking up the different breast cancer morphologies namely mass, pathological calcifications, asymmetry, and distortion was assessed. Tissue biopsy and pathology were used as the standard reference. The study included 123 female patients with 134 proved carcinoma. All patients underwent digital mammogram (DM) examination scanned with artificial intelligence algorithm.

Results

AI achieved higher sensitivity than mammography in detecting malignant breast lesions. The sensitivity of AI was 96.6%, and false negative rate was 3.4%, while mammography sensitivity was 87.3% and false negative rate 12.7%. Our study showed AI performed better than mammography in detecting ductal carcinoma in situ and invasive lobular carcinoma with sensitivity (100% and 96.6%) vs (88.9% and 82.2%) respectively. AI was more sensitive to detect cancers presented with suspicious mass 95.2% vs 75%, suspicious calcifications 100% vs 86.5% and asymmetry and distortion 100% vs 84.6%, than mammography.

Conclusions

AI showed potential values to overcome mammographic limitations in the detection of breast cancer even those with challenging morphology as invasive lobular carcinoma, ductal carcinoma in situ, tubular carcinoma and micropapillary carcinoma.

Effects of a continuous nursing care model on elderly patients with total hip arthroplasty: a randomized controlled trial

BACKGROUND

Continuous nursing care (CNC) is an extended service based on meeting the needs of discharged patients for post-discharge treatment and rehabilitation. This research aimed to investigate the effects of CNC on older patients with total hip arthroplasty and to offer a scientific basis for improving the prognosis.

METHODS

A total of 134 patients with total hip arthroplasty were randomly divided into the control group (n = 67) and the intervention group (n = 67). The control group was treated by conventional nursing care and the intervention group was treated by CNC. Harris hip score, Barthel index, the activities of daily living (ADL) scale, self-rating depression scale (SDS) and self-rating anxiety scale (SAS) in these two groups were evaluated. Demographic characteristics between groups were analyzed by unpaired t test. The observation indexes between groups were assessed by two-way ANOVA test followed by Tukey's multiple comparisons test.

RESULTS

The scores of Harris hip score, Barthel index, ADL, SDS and SAS in the intervention group after intervention and after follow-up were better than the intervention group before intervention (all p < 0.01). Meanwhile, the scores of Harris hip score, Barthel index, ADL, SDS and SAS in the intervention group were better than the control group both after intervention and after follow-up (all p < 0.01).

CONCLUSION

In conclusion, CNC showed better efficacy than conventional nursing care in promoting hip joint function recovery, improving quality of life and alleviating anxiety and depression for older patients with total hip arthroplasty.

Combined diagnosis of multiparametric MRI-based deep learning models facilitates differentiating triple-negative breast cancer from fibroadenoma magnetic resonance BI-RADS 4 lesions

PURPOSE

To investigate the value of the combined diagnosis of multiparametric MRI-based deep learning models to differentiate triple-negative breast cancer (TNBC) from fibroadenoma magnetic resonance Breast Imaging-Reporting and Data System category 4 (BI-RADS 4) lesions and to evaluate whether the combined diagnosis of these models could improve the diagnostic performance of radiologists.

METHODS

A total of 319 female patients with 319 pathologically confirmed BI-RADS 4 lesions were randomly divided into training, validation, and testing sets in this retrospective study. The three models were established based on contrast-enhanced T1-weighted imaging, diffusion-weighted imaging, and T2-weighted imaging using the training and validation sets. The artificial intelligence (AI) combination score was calculated according to the results of three models. The diagnostic performances of four radiologists with and without AI assistance were compared with the AI combination score on the testing set. The area under the curve (AUC), sensitivity, specificity, accuracy, and weighted kappa value were calculated to assess the performance.

RESULTS

The AI combination score yielded an excellent performance (AUC = 0.944) on the testing set. With AI assistance, the AUC for the diagnosis of junior radiologist 1 (JR1) increased from 0.833 to 0.885, and that for JR2 increased from 0.823 to 0.876. The AUCs of senior radiologist 1 (SR1) and SR2 slightly increased from 0.901 and 0.950 to 0.925 and 0.975 after AI assistance, respectively.

CONCLUSION

Combined diagnosis of multiparametric MRI-based deep learning models to differentiate TNBC from fibroadenoma magnetic resonance BI-RADS 4 lesions can achieve comparable performance to that of SRs and improve the diagnostic performance of JRs.

Impact of artificial intelligence in breast cancer screening with mammography

Objectives

To demonstrate that radiologists, with the help of artificial intelligence (AI), are able to better classify screening mammograms into the correct breast imaging reporting and data system (BI-RADS) category, and as a secondary objective, to explore the impact of AI on cancer detection and mammogram interpretation time.

Methods

A multi-reader, multi-case study with cross-over design, was performed, including 314 mammograms. Twelve radiologists interpreted the examinations in two sessions delayed by a 4 weeks wash-out period with and without AI support. For each breast of each mammogram, they had to mark the most suspicious lesion (if any) and assign it with a forced BI-RADS category and a level of suspicion or “continuous BI-RADS 100”.

Cohen’s kappa correlation coefficient evaluating the inter-observer agreement for BI-RADS category per breast, and the area under the receiver operating characteristic curve (AUC), were used as metrics and analyzed.

Results

On average, the quadratic kappa coefficient increased significantly when using AI for all readers [κ = 0.549, 95% CI (0.528–0.571) without AI and κ = 0.626, 95% CI (0.607–0.6455) with AI]. AUC was significantly improved when using AI (0.74 vs 0.77, p = 0.004). Reading time was not significantly affected for all readers (106 s without AI and vs 102 s with AI; p = 0.754).

Conclusions

When using AI, radiologists were able to better assign mammograms with the correct BI-RADS category without slowing down the interpretation time.

Early detection and classification of abnormality in prior mammograms using image-to-image translation and YOLO techniques

BACKGROUND AND OBJECTIVE

Computer-aided-detection (CAD) systems have been developed to assist radiologists on finding suspicious lesions in mammogram. Deep Learning technology have recently succeeded to increase the chance of recognizing abnormality at an early stage in order to avoid unnecessary biopsies and decrease the mortality rate. In this study, we investigated the effectiveness of an end-to-end fusion model based on You-Only-Look-Once (YOLO) architecture, to simultaneously detect and classify suspicious breast lesions on digital mammograms. Four categories of cases were included: Mass, Calcification, Architectural Distortions, and Normal from a private digital mammographic database including 413 cases. For all cases, Prior mammograms (typically scanned 1 year before) were all reported as Normal, while Current mammograms were diagnosed as cancerous (confirmed by biopsies) or healthy.

METHODS

We propose to apply the YOLO-based fusion model to the Current mammograms for breast lesions detection and classification. Then apply the same model retrospectively to synthetic mammograms for an early cancer prediction, where the synthetic mammograms were generated from the Prior mammograms by using the image-to-image translation models, CycleGAN and Pix2Pix.

RESULTS

Evaluation results showed that our methodology could significantly detect and classify breast lesions on Current mammograms with a highest rate of 93% ± 0.118 for Mass lesions, 88% ± 0.09 for Calcification lesions, and 95% ± 0.06 for Architectural Distortion lesions. In addition, we reported evaluation results on Prior mammograms with a highest rate of 36% ± 0.01 for Mass lesions, 14% ± 0.01 for Calcification lesions, and 50% ± 0.02 for Architectural Distortion lesions. Normal mammograms were accordingly classified with an accuracy rate of 92% ± 0.09 and 90% ± 0.06 respectively on Current and Prior exams.

CONCLUSIONS

Our proposed framework was first developed to help detecting and identifying suspicious breast lesions in X-ray mammograms on their Current screening. The work was also suggested to reduce the temporal changes between pairs of Prior and follow-up screenings for early predicting the location and type of abnormalities in Prior mammogram screening. The paper presented a CAD method to assist doctors and experts to identify the risk of breast cancer presence. Overall, the proposed CAD method incorporates the advances of image processing, deep learning and image-to-image translation for a biomedical application.

Advancements in Oncology with Artificial Intelligence-A Review Article

Well-trained machine learning (ML) and artificial intelligence (AI) systems can provide clinicians with therapeutic assistance, potentially increasing efficiency and improving efficacy. ML has demonstrated high accuracy in oncology-related diagnostic imaging, including screening mammography interpretation, colon polyp detection, glioma classification, and grading. By utilizing ML techniques, the manual steps of detecting and segmenting lesions are greatly reduced. ML-based tumor imaging analysis is independent of the experience level of evaluating physicians, and the results are expected to be more standardized and accurate. One of the biggest challenges is its generalizability worldwide. The current detection and screening methods for colon polyps and breast cancer have a vast amount of data, so they are ideal areas for studying the global standardization of artificial intelligence. Central nervous system cancers are rare and have poor prognoses based on current management standards. ML offers the prospect of unraveling undiscovered features from routinely acquired neuroimaging for improving treatment planning, prognostication, monitoring, and response assessment of CNS tumors such as gliomas. By studying AI in such rare cancer types, standard management methods may be improved by augmenting personalized/precision medicine. This review aims to provide clinicians and medical researchers with a basic understanding of how ML works and its role in oncology, especially in breast cancer, colorectal cancer, and primary and metastatic brain cancer. Understanding AI basics, current achievements, and future challenges are crucial in advancing the use of AI in oncology.

Retrospective Review of Missed Cancer Detection and Its Mammography Findings with Artificial-Intelligence-Based, Computer-Aided Diagnosis

To investigate whether artificial-intelligence-based, computer-aided diagnosis (AI-CAD) could facilitate the detection of missed cancer on digital mammography, a total of 204 women diagnosed with breast cancer with diagnostic (present) and prior mammograms between 2018 and 2020 were included in this study. Two breast radiologists reviewed the mammographic features and classified them into true negative, minimal sign or missed cancer. They analyzed the AI-CAD results with an abnormality score and assessed whether the AI-CAD correctly localized the known cancer sites. Of the 204 cases, 137 were classified as true negative, 33 as minimal signs, and 34 as missed cancer. The sensitivity, specificity and diagnostic accuracy of AI-CAD were 84.7%, 91.5% and 86.3% on diagnostic mammogram and 67.2%, 91.2% and 83.38% on prior mammogram, respectively. The AI-CAD correctly localized 27 cases from 34 missed cancers on prior mammograms. The findings in the preceding mammography of AI-CAD-detected missed cancer were common in the order of calcifications, focal asymmetry and asymmetry. Asymmetry was the most common finding among the seven cases, which could not be detected by AI-CAD in the missed cases (5/7). The assistance of AI-CAD can be helpful in the early detection of breast cancer in mammography screenings.

Independent External Validation of Artificial Intelligence Algorithms for Automated Interpretation of Screening Mammography: A Systematic Review

PURPOSE

The aim of this study was to describe the current state of science regarding independent external validation of artificial intelligence (AI) technologies for screening mammography.

METHODS

A systematic review was performed across five databases (Embase, PubMed, IEEE Explore, Engineer Village, and arXiv) through December 10, 2020. Studies that used screening examinations from real-world settings to externally validate AI algorithms for mammographic cancer detection were included. The main outcome was diagnostic accuracy, defined by area under the receiver operating characteristic curve (AUC). Performance was also compared between radiologists and either stand-alone AI or combined radiologist and AI interpretation. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 tool.

RESULTS

After data extraction, 13 studies met the inclusion criteria (148,361 total patients). Most studies (77% [n = 10]) evaluated commercially available AI algorithms. Studies included retrospective reader studies (46% [n = 6]), retrospective simulation studies (38% [n = 5]), or both (15% [n = 2]). Across 5 studies comparing stand-alone AI with radiologists, 60% (n = 3) demonstrated improved accuracy with AI (AUC improvement range, 0.02-0.13). All 5 studies comparing combined radiologist and AI interpretation with radiologists alone demonstrated improved accuracy with AI (AUC improvement range, 0.028-0.115). Most studies had risk for bias or applicability concerns for patient selection (69% [n = 9]) and the reference standard (69% [n = 9]). Only two studies obtained ground-truth cancer outcomes through regional cancer registry linkage.

CONCLUSIONS

To date, external validation efforts for AI screening mammographic technologies suggest small potential diagnostic accuracy improvements but have been retrospective in nature and suffer from risk for bias and applicability concerns.

Diagnostic Performance of AI for Cancers Registered in A Mammography Screening Program: A Retrospective Analysis

Purpose: To evaluate the performance of an artificial intelligence (AI) algorithm in a simulated screening setting and its effectiveness in detecting missed and interval cancers. Methods: Digital mammograms were collected from Bahcesehir Mammographic Screening Program which is the first organized, population-based, 10-year (2009-2019) screening program in Turkey. In total, 211 mammograms were extracted from the archive of the screening program in this retrospective study. One hundred ten of them were diagnosed as breast cancer (74 screen-detected, 27 interval, 9 missed), 101 of them were negative mammograms with a follow-up for at least 24 months. Cancer detection rates of radiologists in the screening program were compared with an AI system. Three different mammography assessment methods were used: (1) 2 radiologists’ assessment at screening center, (2) AI assessment based on the established risk score threshold, (3) a hypothetical radiologist and AI team-up in which AI was considered to be the third reader. Results: Area under curve was 0.853 (95% CI = 0.801-0.905) and the cut-off value for risk score was 34.5% with a sensitivity of 72.8% and a specificity of 88.3% for AI cancer detection in ROC analysis. Cancer detection rates were 67.3% for radiologists, 72.7% for AI, and 83.6% for radiologist and AI team-up. AI detected 72.7% of all cancers on its own, of which 77.5% were screen-detected, 15% were interval cancers, and 7.5% were missed cancers. Conclusion: AI may potentially enhance the capacity of breast cancer screening programs by increasing cancer detection rates and decreasing false-negative evaluations.

Breast cancer incidence by age at discovery of mammographic abnormality in women participating in French organized screening campaigns

OBJECTIVE

Statistical modeling was already predicted the occurrence/prognosis of breast cancer from previous radiological findings. This study predicts the breast cancer risk by the age at discovery of mammographic abnormality in the French breast cancer screening program.

STUDY DESIGN

This was a cohort study.

METHODS

The study included 261,083 women who meet the inclusion criteria: aged 50-74 years, living in French departments (Ain, Doubs, Haute-Saône, Jura, Territoire-de-Belfort, and Yonne), with at least two mammograms between January 1999 and December 2017, of which the first was 'normal/benign'. The incidence of each abnormality (microcalcifications, spiculated mass, obscured mass, architectural distortion, and asymmetric density) was first estimated, then the breast cancer risk was predicted secondly according to the age at discovery of each mammographic abnormality, using an actuarial life table and a Cox model.

RESULTS

Overall breast cancer (6326 cases) incidence was 3.3 (3.0; 3.1)/1000 person-years. The breast cancer incidence increased proportionally with the discovery age of the speculated mass and microcalcifications. The incidence was twice as high when the spiculated mass age of discovery was ≥70 (12.2 [10.4; 14.4]) compared with age 50-54 years (5.8 [5.1; 6.7]). Depending on the spiculated mass discovery age, the breast cancer risk increased by at least 40% between the age groups 55-59 years (1.4 [1.0; 1.8]) and ≥70 years (2.4 [1.9; 3.3]). Whatever the abnormality, the incidence of breast cancer was higher when it was present in only one breast.

CONCLUSION

The study highlights a stable incidence of breast cancer between successive mammograms, an increased risk of breast cancer with the finding age of spiculated mass and microcalcifications. The reduced delay between the abnormality discovery date and the breast cancer diagnosis date would justify a specific follow-up protocol after the finding of these two abnormalities.

An Automatic Detection and Localization of Mammographic Microcalcifications ROI with Multi-Scale Features Using the Radiomics Analysis Approach

Microcalcifications in breast tissue can be an early sign of breast cancer, and play a crucial role in breast cancer screening. This study proposes a radiomics approach based on advanced machine learning algorithms for diagnosing pathological microcalcifications in mammogram images and provides radiologists with a valuable decision support system (in regard to diagnosing patients). An adaptive enhancement method based on the contourlet transform is proposed to enhance microcalcifications and effectively suppress background and noise. Textural and statistical features are extracted from each wavelet layer's high-frequency coefficients to detect microcalcification regions. The top-hat morphological operator and wavelet transform segment microcalcifications, implying their exact locations. Finally, the proposed radiomic fusion algorithm is employed to classify the selected features into benign and malignant. The proposed model's diagnostic performance was evaluated on the MIAS dataset and compared with traditional machine learning models, such as the support vector machine, K-nearest neighbor, and random forest, using different evaluation parameters. Our proposed approach outperformed existing models in diagnosing microcalcification by achieving an 0.90 area under the curve, 0.98 sensitivity, and 0.98 accuracy. The experimental findings concur with expert observations, indicating that the proposed approach is most effective and practical for early diagnosing breast microcalcifications, substantially improving the work efficiency of physicians.

Use of artificial intelligence for image analysis in breast cancer screening programmes: systematic review of test accuracy

OBJECTIVE

To examine the accuracy of artificial intelligence (AI) for the detection of breast cancer in mammography screening practice.

DESIGN

Systematic review of test accuracy studies.

DATA SOURCES

Medline, Embase, Web of Science, and Cochrane Database of Systematic Reviews from 1 January 2010 to 17 May 2021.

ELIGIBILITY CRITERIA

Studies reporting test accuracy of AI algorithms, alone or in combination with radiologists, to detect cancer in women's digital mammograms in screening practice, or in test sets. Reference standard was biopsy with histology or follow-up (for screen negative women). Outcomes included test accuracy and cancer type detected.

STUDY SELECTION AND SYNTHESIS

Two reviewers independently assessed articles for inclusion and assessed the methodological quality of included studies using the QUality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. A single reviewer extracted data, which were checked by a second reviewer. Narrative data synthesis was performed.

RESULTS

Twelve studies totalling 131 822 screened women were included. No prospective studies measuring test accuracy of AI in screening practice were found. Studies were of poor methodological quality. Three retrospective studies compared AI systems with the clinical decisions of the original radiologist, including 79 910 women, of whom 1878 had screen detected cancer or interval cancer within 12 months of screening. Thirty four (94%) of 36 AI systems evaluated in these studies were less accurate than a single radiologist, and all were less accurate than consensus of two or more radiologists. Five smaller studies (1086 women, 520 cancers) at high risk of bias and low generalisability to the clinical context reported that all five evaluated AI systems (as standalone to replace radiologist or as a reader aid) were more accurate than a single radiologist reading a test set in the laboratory. In three studies, AI used for triage screened out 53%, 45%, and 50% of women at low risk but also 10%, 4%, and 0% of cancers detected by radiologists.

CONCLUSIONS

Current evidence for AI does not yet allow judgement of its accuracy in breast cancer screening programmes, and it is unclear where on the clinical pathway AI might be of most benefit. AI systems are not sufficiently specific to replace radiologist double reading in screening programmes. Promising results in smaller studies are not replicated in larger studies. Prospective studies are required to measure the effect of AI in clinical practice. Such studies will require clear stopping rules to ensure that AI does not reduce programme specificity.

STUDY REGISTRATION

Protocol registered as PROSPERO CRD42020213590.

Diagnostic Performance of Artificial Intelligence-Based Computer-Aided Diagnosis for Breast Microcalcification on Mammography

The present study evaluated the diagnostic performance of artificial intelligence-based computer-aided diagnosis (AI-CAD) compared to that of dedicated breast radiologists in characterizing suspicious microcalcification on mammography. We retrospectively analyzed 435 unilateral mammographies from 420 patients (286 benign; 149 malignant) undergoing biopsy for suspicious microcalcification from June 2003 to November 2019. Commercial AI-CAD was applied to the mammography images, and malignancy scores were calculated. Diagnostic performance was compared between radiologists and AI-CAD using the area under the receiving operator characteristics curve (AUC). The AUCs of radiologists and AI-CAD were not significantly different (0.722 vs. 0.745, p = 0.393). The AUCs of the adjusted category were 0.726, 0.744, and 0.756 with cutoffs of 2%, 10%, and 38.03% for AI-CAD, respectively, which were all significantly higher than those for radiologists alone (all p < 0.05). None of the 27 cases downgraded to category 3 with a cutoff of 2% were confirmed as malignant on pathological analysis, suggesting that unnecessary biopsies could be avoided. Our findings suggest that the diagnostic performance of AI-CAD in characterizing suspicious microcalcification on mammography was similar to that of the radiologists, indicating that it may aid in making clinical decisions regarding the treatment of breast microcalcification.

Keratoconus detection of changes using deep learning of colour-coded maps

Objective

To evaluate the accuracy of convolutional neural networks technique (CNN) in detecting keratoconus using colour-coded corneal maps obtained by a Scheimpflug camera.

Design

Multicentre retrospective study.

Methods and analysis

We included the images of keratoconic and healthy volunteers’ eyes provided by three centres: Royal Liverpool University Hospital (Liverpool, UK), Sedaghat Eye Clinic (Mashhad, Iran) and The New Zealand National Eye Center (New Zealand). Corneal tomography scans were used to train and test CNN models, which included healthy controls. Keratoconic scans were classified according to the Amsler-Krumeich classification. Keratoconic scans from Iran were used as an independent testing set. Four maps were considered for each scan: axial map, anterior and posterior elevation map, and pachymetry map.

Results

A CNN model detected keratoconus versus health eyes with an accuracy of 0.9785 on the testing set, considering all four maps concatenated. Considering each map independently, the accuracy was 0.9283 for axial map, 0.9642 for thickness map, 0.9642 for the front elevation map and 0.9749 for the back elevation map. The accuracy of models in recognising between healthy controls and stage 1 was 0.90, between stages 1 and 2 was 0.9032, and between stages 2 and 3 was 0.8537 using the concatenated map.

Conclusion

CNN provides excellent detection performance for keratoconus and accurately grades different severities of disease using the colour-coded maps obtained by the Scheimpflug camera. CNN has the potential to be further developed, validated and adopted for screening and management of keratoconus.

A Review of Applications of Machine Learning in Mammography and Future Challenges

BACKGROUND

The aim of this study is to systematically review the literature to summarize the evidence surrounding the clinical utility of artificial intelligence (AI) in the field of mammography. Databases from PubMed, IEEE Xplore, and Scopus were searched for relevant literature. Studies evaluating AI models in the context of prediction and diagnosis of breast malignancies that also reported conventional performance metrics were deemed suitable for inclusion. From 90 unique citations, 21 studies were considered suitable for our examination. Data was not pooled due to heterogeneity in study evaluation methods.

SUMMARY

Three studies showed the applicability of AI in reducing workload. Six studies demonstrated that AI can aid in diagnosis, with up to 69% reduction in false positives and an increase in sensitivity ranging from 84 to 91%. Five studies show how AI models can independently mark and classify suspicious findings on conventional scans, with abilities comparable with radiologists. Seven studies examined AI predictive potential for breast cancer and risk score calculation. Key Messages: Despite limitations in the current evidence base and technical obstacles, this review suggests AI has marked potential for extensive use in mammography. Additional works, including large-scale prospective studies, are warranted to elucidate the clinical utility of AI.

A review on recent advancements in diagnosis and classification of cancers using artificial intelligence

Artificial intelligence has illustrated drastic changes in radiology and medical imaging techniques which in turn led to tremendous changes in screening patterns. In particular, advancements in these techniques led to the development of computer aided detection (CAD) strategy. These approaches provided highly accurate diagnostic reports which served as a "second-opinion" to the radiologists. However, with significant advancements in artificial intelligence strategy, the diagnostic and classifying capabilities of CAD system are meeting the levels of radiologists and clinicians. Thus, it shifts the CAD system from second opinion approach to a high utility tool. This article reviews the strategies and algorithms developed using artificial intelligence for the foremost cancer diagnosis and classification which overcomes the challenges in the traditional method. In addition, the possible direction of AI in medical aspects is also discussed in this study.

Nanogenomics and Artificial Intelligence: A Dynamic Duo for the Fight Against Breast Cancer

Application software is utilized to aid in the diagnosis of breast cancer. Yet, recent advances in artificial intelligence (AI) are addressing challenges related to the detection, classification, and monitoring of different types of tumors. AI can apply deep learning algorithms to perform automated analysis on mammographic or histologic examinations. Large volume of data generated by digitalized mammogram or whole-slide images can be interoperated through advanced machine learning. This enables fast evaluation of every tissue patch on an image, resulting in a quicker more sensitivity, and more reproducible diagnoses compared to human performance. On the other hand, cancer cell-exosomes which are extracellular vesicles released by cancer cells into the blood circulation, are being explored as cancer biomarker. Recent studies on cancer-exosome-content revealed that the encapsulated miRNA and other biomolecules are indicative of tumor sub-type, possible metastasis and prognosis. Thus, theoretically, through nanogenomicas, a profile of each breast tumor sub-type, estrogen receptor status, and potential metastasis site can be constructed. Then, a laboratory instrument, fitted with an AI program, can be used to diagnose suspected patients by matching their sera miRNA and biomolecules composition with the available template profiles. In this paper, we discuss the advantages of establishing a nanogenomics-AI-based breast cancer diagnostic approach, compared to the gold standard radiology or histology based approaches that are currently being adapted to AI. Also, we discuss the advantages of building the diagnostic and prognostic biomolecular profiles for breast cancers based on the exosome encapsulated content, rather than the free circulating miRNA and other biomolecules.

Association of Clinician Diagnostic Performance With Machine Learning-Based Decision Support Systems: A Systematic Review

IMPORTANCE

An increasing number of machine learning (ML)-based clinical decision support systems (CDSSs) are described in the medical literature, but this research focuses almost entirely on comparing CDSS directly with clinicians (human vs computer). Little is known about the outcomes of these systems when used as adjuncts to human decision-making (human vs human with computer).

OBJECTIVES

To conduct a systematic review to investigate the association between the interactive use of ML-based diagnostic CDSSs and clinician performance and to examine the extent of the CDSSs' human factors evaluation.

EVIDENCE REVIEW

A search of MEDLINE, Embase, PsycINFO, and grey literature was conducted for the period between January 1, 2010, and May 31, 2019. Peer-reviewed studies published in English comparing human clinician performance with and without interactive use of an ML-based diagnostic CDSSs were included. All metrics used to assess human performance were considered as outcomes. The risk of bias was assessed using Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) and Risk of Bias in Non-Randomised Studies-Intervention (ROBINS-I). Narrative summaries were produced for the main outcomes. Given the heterogeneity of medical conditions, outcomes of interest, and evaluation metrics, no meta-analysis was performed.

FINDINGS

A total of 8112 studies were initially retrieved and 5154 abstracts were screened; of these, 37 studies met the inclusion criteria. The median number of participating clinicians was 4 (interquartile range, 3-8). Of the 107 results that reported statistical significance, 54 (50%) were increased by the use of CDSSs, 4 (4%) were decreased, and 49 (46%) showed no change or an unclear change. In the subgroup of studies carried out in representative clinical settings, no association between the use of ML-based diagnostic CDSSs and improved clinician performance could be observed. Interobserver agreement was the commonly reported outcome whose change was the most strongly associated with CDSS use. Four studies (11%) reported on user feedback, and, in all but 1 case, clinicians decided to override at least some of the algorithms' recommendations. Twenty-eight studies (76%) were rated as having a high risk of bias in at least 1 of the 4 QUADAS-2 core domains, and 6 studies (16%) were considered to be at serious or critical risk of bias using ROBINS-I.

CONCLUSIONS AND RELEVANCE

This systematic review found only sparse evidence that the use of ML-based CDSSs is associated with improved clinician diagnostic performance. Most studies had a low number of participants, were at high or unclear risk of bias, and showed little or no consideration for human factors. Caution should be exercised when estimating the current potential of ML to improve human diagnostic performance, and more comprehensive evaluation should be conducted before deploying ML-based CDSSs in clinical settings. The results highlight the importance of considering supported human decisions as end points rather than merely the stand-alone CDSSs outputs.

Automated detection and segmentation of focal cortical dysplasias (FCDs) with artificial intelligence: Presentation of a novel convolutional neural network and its prospective clinical validation

PURPOSE

Focal cortical dysplasias (FCDs) represent one of the most frequent causes of pharmaco-resistant focal epilepsies. Despite improved clinical imaging methods over the past years, FCD detection remains challenging, as FCDs vary in location, size, and shape and commonly blend into surrounding tissues without clear definable boundaries. We developed a novel convolutional neural network for FCD detection and segmentation and validated it prospectively on daily-routine MRIs.

MATERIAL AND METHODS

The neural network was trained on 201 T1 and FLAIR 3 T MRI volume sequences of 158 patients with mainly FCDs, regardless of type, and 7 focal PMG. Non-FCD/PMG MRIs, drawn from 100 normal MRIs and 50 MRIs with non-FCD/PMG pathologies, were added to the training. We applied the algorithm prospectively on 100 consecutive MRIs of patients with focal epilepsy from daily clinical practice. The results were compared with corresponding neuroradiological reports and morphometric MRI analyses evaluated by an experienced epileptologist.

RESULTS

Best training results reached a sensitivity (recall) of 70.1 % and a precision of 54.3 % for detecting FCDs. Applied on the daily-routine MRIs, 7 out of 9 FCDs were detected and segmented correctly with a sensitivity of 77.8 % and a specificity of 5.5 %. The results of conventional visual analyses were 33.3 % and 94.5 %, respectively (3/9 FCDs detected); the results of morphometric analyses with overall epileptologic evaluation were both 100 % (9/9 FCDs detected) and thus served as reference.

CONCLUSION

We developed a 3D convolutional neural network with autoencoder regularization for FCD detection and segmentation. Our algorithm employs the largest FCD training dataset to date with various types of FCDs and some focal PMG. It provided a higher sensitivity in detecting FCDs than conventional visual analyses. Despite its low specificity, the number of false positively predicted lesions per MRI was lower than with morphometric analysis. We consider our algorithm already useful for FCD pre-screening in everyday clinical practice.

Improving Breast Cancer Detection Accuracy of Mammography with the Concurrent Use of an Artificial Intelligence Tool

Purpose

To evaluate the benefits of an artificial intelligence (AI)-based tool for two-dimensional mammography in the breast cancer detection process.

Materials and Methods

In this multireader, multicase retrospective study, 14 radiologists assessed a dataset of 240 digital mammography images, acquired between 2013 and 2016, using a counterbalance design in which half of the dataset was read without AI and the other half with the help of AI during a first session and vice versa during a second session, which was separated from the first by a washout period. Area under the receiver operating characteristic curve (AUC), sensitivity, specificity, and reading time were assessed as endpoints.

Results

The average AUC across readers was 0.769 (95% CI: 0.724, 0.814) without AI and 0.797 (95% CI: 0.754, 0.840) with AI. The average difference in AUC was 0.028 (95% CI: 0.002, 0.055, P = .035). Average sensitivity was increased by 0.033 when using AI support (P = .021). Reading time changed dependently to the AI-tool score. For low likelihood of malignancy (< 2.5%), the time was about the same in the first reading session and slightly decreased in the second reading session. For higher likelihood of malignancy, the reading time was on average increased with the use of AI.

Conclusion

This clinical investigation demonstrated that the concurrent use of this AI tool improved the diagnostic performance of radiologists in the detection of breast cancer without prolonging their workflow.Supplemental material is available for this article.© RSNA, 2020.

Artificial Intelligence: A Primer for Breast Imaging Radiologists

Artificial intelligence (AI) is a branch of computer science dedicated to developing computer algorithms that emulate intelligent human behavior. Subfields of AI include machine learning and deep learning. Advances in AI technologies have led to techniques that could increase breast cancer detection, improve clinical efficiency in breast imaging practices, and guide decision-making regarding screening and prevention strategies. This article reviews key terminology and concepts, discusses common AI models and methods to validate and evaluate these models, describes emerging AI applications in breast imaging, and outlines challenges and future directions. Familiarity with AI terminology, concepts, methods, and applications is essential for breast imaging radiologists to critically evaluate these emerging technologies, recognize their strengths and limitations, and ultimately ensure optimal patient care.

Reinforcement Learning for Clinical Decision Support in Critical Care: Comprehensive Review

BACKGROUND

Decision support systems based on reinforcement learning (RL) have been implemented to facilitate the delivery of personalized care. This paper aimed to provide a comprehensive review of RL applications in the critical care setting.

OBJECTIVE

This review aimed to survey the literature on RL applications for clinical decision support in critical care and to provide insight into the challenges of applying various RL models.

METHODS

We performed an extensive search of the following databases: PubMed, Google Scholar, Institute of Electrical and Electronics Engineers (IEEE), ScienceDirect, Web of Science, Medical Literature Analysis and Retrieval System Online (MEDLINE), and Excerpta Medica Database (EMBASE). Studies published over the past 10 years (2010-2019) that have applied RL for critical care were included.

RESULTS

We included 21 papers and found that RL has been used to optimize the choice of medications, drug dosing, and timing of interventions and to target personalized laboratory values. We further compared and contrasted the design of the RL models and the evaluation metrics for each application.

CONCLUSIONS

RL has great potential for enhancing decision making in critical care. Challenges regarding RL system design, evaluation metrics, and model choice exist. More importantly, further work is required to validate RL in authentic clinical environments.